UMIN-CTR Clinical Trial

Unique ID issued by UMIN C000000030
Receipt number R000000064
Scientific Title A randomized controlled trial to evaluate the efficacy of intra-pericardial instillation of a sclerosing agent after pericardial drainage in patients with malignant pericardial effusion associated with lung cancer (JCOG9811).
Date of disclosure of the study information 2005/07/28
Last modified on 2014/08/13 13:58:49

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A randomized controlled trial to evaluate the efficacy of intra-pericardial instillation of a sclerosing agent after pericardial drainage in patients with malignant pericardial effusion associated with lung cancer (JCOG9811).

Acronym

A randomized controlled trial to evaluate the efficacy of intra-pericardial instillation of a sclerosing agent after pericardial drainage in patients with malignant pericardial effusion associated with lung cancer (JCOG9811).

Scientific Title

A randomized controlled trial to evaluate the efficacy of intra-pericardial instillation of a sclerosing agent after pericardial drainage in patients with malignant pericardial effusion associated with lung cancer (JCOG9811).

Scientific Title:Acronym

A randomized controlled trial to evaluate the efficacy of intra-pericardial instillation of a sclerosing agent after pericardial drainage in patients with malignant pericardial effusion associated with lung cancer (JCOG9811).

Region

Japan


Condition

Condition

Malignant pericardial effusion

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy of pericardial instillation of bleomycin as sclerosing agent after pericardial drainage for lung cancer-associated malignant pericardial effusion.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Phase III


Assessment

Primary outcomes

Survival without pericardial effusion at 2 months

Key secondary outcomes

Succesful extubation of pericardial drainage tube, time to extubation, survival without pericardial effusion at 1,2,4,6,12months, symptom palliation, complication, long-term (>6months) effect on cardiac function.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation

NO

Institution consideration


Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Observation alone after pericardial drainage

Interventions/Control_2

Percardial instillation of bleomycin after pericardial drainage

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

1)pathologically documented lung cancer
2)clinically stable condition after pericardial drainage for malignant pericardial effusion (not necessary to be documented by cytology)
3)expected to live 6 weeks or longer
4)sufficient organ function
5)signed informed consent

Key exclusion criteria

1)Myocardial infarction or unstable angina within 3 months
2)constricitive pericarditis
3)active pneumonitis
4)severe infection or DIC
5)other severe co-morbidity which could not be relieved with pericardial drainage
6)chemotherapy-naive small cell lung cancer

Target sample size

80


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tomohide Tamura, M.D.

Organization

National Cancer Center Hospital

Division name

Medical Oncology Division

Zip code


Address

5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, JAPAN

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Hideo Kunitoh, M.D.

Organization

JCOG9811 Coordinating Office

Division name

Medical Oncology Division, National Cancer Center Hospital

Zip code


Address

5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, JAPAN

TEL


Homepage URL

http://www.jcog.jp/

Email

JCOG_sir@ml.jcog.jp


Sponsor or person

Institute

Japan Clinical Oncology Group(JCOG)

Institute

Department

Personal name



Funding Source

Organization

Ministry of Health, Labour and Welfare

Organization

Division

Category of Funding Organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

YES

Study ID_1

NCT00132613

Org. issuing International ID_1

ClinicalTrials.gov by NLM

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立病院機構道北病院 (北海道)
国立病院機構北海道がんセンター(北海道)
旭川医科大学 (北海道)
東北大学病院 (宮城県)
山形県立中央病院 (山形県)
茨城県立中央病院・茨城県地域がんセンター(茨城県)
栃木県立がんセンター(栃木県)
国立病院機構西群馬病院 (群馬県)
群馬県立がんセンター(群馬県)
埼玉県立がんセンター(埼玉県)
国立がんセンター東病院 (千葉県)
国立がんセンター中央病院 (東京都)
国立国際医療センター(東京都)
東京慈恵会医科大学青戸病院 (東京都)
癌研究会有明病院 (東京都)
都立駒込病院 (東京都)
神奈川県立がんセンター(神奈川県)
横浜市立市民病院(神奈川県)
新潟県立がんセンター新潟病院 (新潟県)
岐阜市民病院 (岐阜県)
愛知県がんセンター中央病院 (愛知県)
国立病院機構名古屋医療センター(愛知県)
愛知県がんセンター愛知病院 (愛知県)
大阪市立大学大学院医学研究科(大阪府)
近畿大学医学部(大阪府)
大阪府立病院機構大阪府立成人病センター(大阪府)
大阪府立病院機構大阪府立呼吸器・アレルギー医療センター(大阪府)
国立病院機構近畿中央胸部疾患センター(大阪府)
国立病院機構刀根山病院 (大阪府)
りんくう総合医療センター市立泉佐野病院 (大阪府)
神戸市立中央市民病院 (兵庫県)
兵庫医科大学 (兵庫県)
国立病院機構四国がんセンター(愛媛県)
九州大学病院 (福岡県)
長崎大学医学部・歯学部附属病院 (長崎県)
熊本地域医療センター(熊本県)


Other administrative information

Date of disclosure of the study information

2005 Year 07 Month 28 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

http://www.ncbi.nlm.nih.gov/pubmed/19156149

Number of participants that the trial has enrolled


Results

See the datails via "URL releasing results" above.
Also the details can be seen in the JCOG website:
http://www.jcog.jp/en/trials/index.html

Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

1999 Year 07 Month 23 Day

Date of IRB


Anticipated trial start date

1999 Year 08 Month 01 Day

Last follow-up date

2006 Year 11 Month 01 Day

Date of closure to data entry

2006 Year 12 Month 01 Day

Date trial data considered complete

2006 Year 12 Month 01 Day

Date analysis concluded

2006 Year 12 Month 01 Day


Other

Other related information



Management information

Registered date

2005 Year 07 Month 28 Day

Last modified on

2014 Year 08 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000064